In response to the growing problem of the abuse, misuse and diversion of Extended Release/Long Acting (ER/LA) Opioid drugs, the FDA approved a risk evaluation and mitigation strategy (REMS) for ER/LA opioid medications.
The American Society of Addiction Medicine (ASAM) has received funding to train over two thousand prescribers in accordance with the guidelines set forth by the FDA. ASAM is looking for ways to reach out and train new populations of ER/LA Opioid Prescribers.
The ER/LA Opioid REMS Course Webinar will stream live from the on-site course in Orlando, FL on Wednesday, September 17, 2014. There are no fees for ASAM’s ER/LA Opioid REMS course but all attendees must register in advance or on site. Participants can earn up to 3 AMA PRA Category 1 CME credit(s)™ upon completion of the course assessment and evaluation.
For more information about ASAM’s ER/LA Opioid REMS Course please click here.